Introduction
Type 2 diabetes mellitus involves defects in both insulin secretion and insulin sensitivity. Multiple insulin secretion defects could occur, including the absence of pulsatility [1] , loss of the early phase of insulin secretion after glucose stimulation [2] , decreased basal and stimulated concentrations of insulin in the plasma [3] , excess secretion of pro-hormone, and progressive decreases in insulin secretory capacity [4] . Thus, the regulation of insulin secretion in pancreatic β cells has long been considered important for the prevention and treatment of type 2 diabetes mellitus [4] . Emerging data have shown that GLP-1 functions through its receptor to regulate insulin secretion and glucose metabolism and is, therefore, a potentially important target in the treatment of type 2 diabetes. GLP-1 is able to improve insulin secretion in subjects with impaired glucose tolerance and type 2 diabetes [5] . Studies have demonstrated that increased expression or activity of GLP-1R is beneficial to β cell functions, including insulin synthesis/secretion [6] , proliferation [7] , neogenesis [7] , and anti-apoptosis [8] . Unfortunately, GLP-1 has a half-life of less than 2 minutes in the circulatory system owing to rapid degradation by dipeptidyl peptidase-4 (DPP IV) [9] . Utilizing a high-throughput screening assay, we previously identified geniposide as a potent agonist of GLP-1R and possessed neurotrophic and neuroprotective properties [10] [11] [12] . However, it is unknown whether geniposide is able to improve insulin secretion in pancreatic β cells. In the present study we examined the effect of geniposide on insulin secretion in INS-1 cells. The results demonstrate that geniposide increased insulin secretion in a dose-dependent manner and enhanced glucose-stimulated insulin secretion in INS-1 cells. We have further observed that exendin , an antagonist of GLP-1R, and GLP-1R siRNA decreased the effect of geniposide on glucose-stimulated insulin secretion in INS-1 cells.
Materials and methods

Cell culture
An INS-1 rat insulinoma cell line was purchased from the CCTCC (China Center for Type Culture Collection). The cells 
Effect of geniposide on insulin secretion stimulated by glucose
To explore the influence of geniposide on glucose-stimulated insulin secretion, INS-1 cells were seeded onto 12-well plates and cultured for 24 h. After the cells were washed two times with fresh KRBH and starved for 2 h in fresh KRBH, the cells were incubated with 10 μmol/L geniposide in the absence or presence of indicated concentrations of glucose for 1 h. The supernatants were collected and analyzed for insulin concentration using commercial kit (Linco Research, Inc, Missouri, USA) according to the kit' instructions.
The role of GLP-1R in geniposide-inducing insulin secretion
To probe the role of GLP-1R, we investigated the effect of an antagonist for GLP-1R on insulin secretion in the presence of a low concentration of glucose. INS-1 cells were starved for 2 h in fresh KRBH, placed for 1 h in fresh KRBH containing 200 nmol/L exendin (9-39), and then treated for 1 h with 5.5 mmol/L glucose in the presence or absence of 10 μmol/L geniposide. The supernatants were collected to probe the insulin concentration using commercial kits.
To further explore the role of GLP-1R in the regulatory effects of geniposide on insulin secretion, we constructed a stable INS-1 cell line with the GLP-1R silenced by a shGLP-1R plasmid, which was optimized in our previous work [11] . The level of GLP-1R expression was analyzed with Western blot and real-time PCR. The primers were 5'-TATTGGCT-CATCATACGCTTG-3' (GLP-1R sense), 5'-GTCTGCATTTG ATGTCGGTCT-3' (GLP-1R antisense), 5'-AAGTTCAACG-GCACAGTCAAG-3' (GAPDH sense) and 5'-CCAGTA-GACTCCACGACATACTCA-3' (GAPDH antisense). The mRNA and protein levels of GLP-1R are about 35.4% and 21% those of the control, respectively. Using the same protocol as introduced in Materials and Methods, we determined the insulin secretion induced by geniposide in INS-1 cells in which GLP-1R had been knocked down.
Statistical analysis
Data are expressed as the means±SD from at least three independent experiments. When significance was detected, the differences between the treatments were analyzed using a one-way ANOVA with the Origin 8.0 Pair-Sample t-Test. The significance level was set at P<0.05.
Results
Geniposide regulates insulin secretion in INS-1 cells As shown in Figure 1 , geniposide elicited concentrationdependent increases in insulin secretion in β cells. Similar to GLP-1, geniposide also increased acute insulin secretion in response to both low and moderately high glucose levels (Figure 2) .
In normoglycemic subjects, glucose-stimulated insulin secretion is characterized by a biphasic pattern, with the peak of the first phase rising abruptly 3-5 min after glucose stimulation and lasting for about 10 min [4] . To determine whether geniposide induces changes in both phases of insulin secretion, we tested the influence of geniposide on biphasic insulin secretion in INS-1 cells in the absence or presence of low glucose levels. It was observed that geniposide enhanced insulin secretion in both phases when glucose was present (Figure 3 ).
GLP-1R plays an important role in geniposide-induced insulin secretion in INS-1 cells.
Our previous work showed that geniposide was an agonist of GLP-1R [10] [11] [12] . To investigate the role of GLP-1R in glucosestimulated insulin secretion, we determined the effect of 
Discussion
Type 2 diabetes mellitus is a metabolic disorder that manifests mainly as abnormalities in pancreatic insulin secretion and the peripheral actions of insulin. During the progression of diabetes, the mass of β cells is reduced, with a concomitant decrease in the amount of insulin secreted. An effective therapeutic option is to use drugs to boost the production and release of insulin by pancreatic islets. For example, sulfonylurea-based drugs that act on the β-cell secretory apparatus augment the release of insulin, overcoming peripheral insulin resistance and restoring normoglycemia in type 2 diabetic patients. Nonetheless, treatment with sulfonylureas is associated with side-effects, such as non-optimal normoglycemic control, which triggers protracted hypoglycemic episodes, worsens myocardial function, and potentially causes weight gain [13, 14] . Alternatively, natural hypoglycemic compounds may offer [15] . In the present study, we examined the effect of geniposide, one of the main iridoid glucoside of Gardenia fruit, on insulin secretion and GLP-1R. We found, for the first time, that geniposide induces insulin secretion in β-cells in a dose-dependent manner and that geniposide has a synergistic effect on insulin secretion in INS-1 cells in the presence of low and moderately high doses of glucose. We also observed that geniposide directly induced insulin secretion in INS-1 cells in the absence of glucose. These results may be a consequence of the activation of GLP-1R by geniposide, which regulates the concentration of Ca 2+ through a signal pathway, or changes in the energy balance of INS-1 cells, which alters the ATP ratio and further regulates the activity of ATP-sensitive K + channels. GLP-1 is an incretin, which is released in response to carbohydrate and fat intake and enhances glucose-stimulated insulin secretion [16] . An increasing number of studies have demonstrated the benefits of GLP-1 for increasing pancreatic β cell mass and function. Because GLP-1 exerts its beneficial effects through binding and activating its receptor, GLP-1R is a valuable target for the treatment of diabetes [17] . However, GLP-1 has an extremely short half-life owing to rapid degradation by DPP IV, which limits the therapeutic value of exogenous GLP-1 [9] . Therefore, it is important to develop small molecules that are able to activate GLP-1R. The ability of geniposide to activate GLP-1R has previously been demonstrated in neurons [10, 12] . However, the effects of this compound on the regulation of insulin secretion and GLP-1R are poorly understood. It is conceivable that GLP-1R agonists can play a role as anti-diabetic agents and as tools for researching islet metabolism. Nevertheless, our findings about the action of geniposide on β-cell insulin secretion warrant investigation into the molecular mechanisms involved. Moreover, we also observed that both exendin (9-39) and GLP-1R siRNA off-set the effect of geniposide on insulin secretion, suggesting that GLP-1R plays a critical role in the geniposide-induced increase in insulin secretion by INS-1 cells.
Additionally, the observed increase in glucose-stimulated insulin secretion in INS-1 cells following incubation with geniposide was especially evident during the first-phase of insulin secretion. In type 2 diabetes mellitus, the first-phase of insulin secretion is abolished and late phase secretion is reduced and delayed [18] . The early phase of insulin secretion is pivotal in the transition from the fasting state to the fed state with a different function [19] . A reduction in the firstphase of insulin secretion has been found both in patients with overt type 2 diabetes mellitus and at the early stage of disease development, which involves impaired glucose tolerance and a slightly elevated fasting glucose [20] . The effect of geniposide on insulin secretion through activation of GLP-1R suggests that geniposide may be a potential therapeutic agent for the prevention or treatment of type 2 diabetes.
